Vimian Group AB (publ) VIMIAN
This picture changes. Follow Vimian Group AB (publ) free — email when the signal or risk changes + a Sunday weekly brief.
Follow Vimian Group AB (publ) freeEmail when the signal or risk changes · Sunday weekly brief
No card · No time limit on free tier · Upgrade when you need more
Full analysis: 6 Apr 2026
Latest news check: 18 Jul 2026
General analysis — not personal advice.
HOLD
7/10
Confidence
Hold; consider adding 10-20% after Q1 confirmation.
Hold given the quality animal-health exposure and solid cash generation.
- Wait for clearer evidence on the MedTech turnaround and leadership stability.
- Upside exists, but execution risk is elevated in the near/medium term.
Market sentiment
7/10
→
Trend: Stable
Sentiment has improved to mildly positive on the Q4 beat and clearer leadership direction, but investors remain cautious on execution (especially MedTech/US) and acquisition integration risk.
Risk assessment
6/10
Dilution:
Low
Positive cash flow; LTIP dilution appears limited
Jurisdiction:
Low
Mainly Sweden, North America, Western Europe
Execution:
High
Management turnover and US MedTech turnaround
Recent changes
- New information in the latest analysis: Vimian reported a Q4 result that beat expectations and the share rose about 6.5% around the release. No EPS/revenue figures or guidance were provided.
About the company
Vimian Group AB (publ) is a global animal health group operating across Specialty Pharma, MedTech, Diagnostics, and Veterinary Services. The company grows through organic initiatives and acquisitions, but near-term uncertainty is elevated due to MedTech weakness and ongoing management changes.
Sector:
Animal health (veterinary pharma, diagnostics and medtech)
Type:
Other
Next report
22 Oct 2026
Q3
Catalysts
22 Oct 2026
Q3 2026 report
High
Unknown
M&A and integration (bolt-ons)
Medium
Unknown
Working capital and leverage
Medium
Horizon:
Bull case
Sustained double-digit organic growth and a stable EBITA margin, with a clear MedTech improvement, could support a higher valuation if cash conversion normalises.
Bear case
Weak cash conversion and rising working capital alongside higher net debt may shift attention to the balance sheet and cap upside despite solid earnings growth.
Signal rationale (informational)
Hold given the quality animal-health exposure and solid cash generation.
- Wait for clearer evidence on the MedTech turnaround and leadership stability.
- Upside exists, but execution risk is elevated in the near/medium term.
Recent news
- On 17 Jul 2026, Vimian reported Q2 2026: revenue of EUR 121.6m (+17% y/y) with 12% organic growth and adjusted EBITA of EUR 29.7m (+17%) with a 24.5% margin; MedTech returned to double-digit organic growth. At the same time, operating cash flow fell to EUR 3.8m (22.2) driven by higher working capital, and net debt increased to EUR 273.7m (~2.1x adjusted EBITDA). The share price reacted positively after the report.
Price & valuation
Last close
SEK 35.30
1 week
+3.5 %
3 months
+17.1 %
12 months
+11.5 %
From 52w high
-0.1 %
From 52w low
+41.7 %
Exchange
Stockholm
Sector
Animal health (veterinary pharma, diagnostics and medtech)
This picture changes. Follow Vimian Group AB (publ) free — email when the signal or risk changes + a Sunday weekly brief.
Follow 3 companies freeEmail when the signal or risk changes · Sunday weekly brief
No card · No time limit on free tier · Upgrade when you need more
Firelda provides general information and analysis, not personal investment advice. Content does not consider your financial situation or goals. Investments can rise and fall in value. Always do your own research.